Literature DB >> 25866901

The mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transport.

Natalie L Trevaskis1, Luojuan Hu2, Suzanne M Caliph2, Sifei Han2, Christopher J H Porter3.   

Abstract

The intestinal lymphatic system plays key roles in fluid transport, lipid absorption and immune function. Lymph flows directly from the small intestine via a series of lymphatic vessels and nodes that converge at the superior mesenteric lymph duct. Cannulation of the mesenteric lymph duct thus enables the collection of mesenteric lymph flowing from the intestine. Mesenteric lymph consists of a cellular fraction of immune cells (99% lymphocytes), aqueous fraction (fluid, peptides and proteins such as cytokines and gut hormones) and lipoprotein fraction (lipids, lipophilic molecules and apo-proteins). The mesenteric lymph duct cannulation model can therefore be used to measure the concentration and rate of transport of a range of factors from the intestine via the lymphatic system. Changes to these factors in response to different challenges (e.g., diets, antigens, drugs) and in disease (e.g., inflammatory bowel disease, HIV, diabetes) can also be determined. An area of expanding interest is the role of lymphatic transport in the absorption of orally administered lipophilic drugs and prodrugs that associate with intestinal lipid absorption pathways. Here we describe, in detail, a mesenteric lymph duct cannulated rat model which enables evaluation of the rate and extent of lipid and drug transport via the lymphatic system for several hours following intestinal delivery. The method is easily adaptable to the measurement of other parameters in lymph. We provide detailed descriptions of the difficulties that may be encountered when establishing this complex surgical method, as well as representative data from failed and successful experiments to provide instruction on how to confirm experimental success and interpret the data obtained.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25866901      PMCID: PMC4401200          DOI: 10.3791/52389

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  44 in total

1.  Isolated rabbit enterocytes as a model cell system for investigations of chylomicron assembly and secretion.

Authors:  I J Cartwright; J A Higgins
Journal:  J Lipid Res       Date:  1999-07       Impact factor: 5.922

2.  Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion.

Authors:  C J Porter; S A Charman; W N Charman
Journal:  J Pharm Sci       Date:  1996-04       Impact factor: 3.534

3.  A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport.

Authors:  Natalie L Trevaskis; Suzanne M Caliph; Gary Nguyen; Patrick Tso; William N Charman; Christopher J H Porter
Journal:  Pharm Res       Date:  2013-02-21       Impact factor: 4.200

4.  A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.

Authors:  S M Khoo; G A Edwards; C J Porter; W N Charman
Journal:  J Pharm Sci       Date:  2001-10       Impact factor: 3.534

Review 5.  Lymphatic lipid transport: sewer or subway?

Authors:  J Brandon Dixon
Journal:  Trends Endocrinol Metab       Date:  2010-06-11       Impact factor: 12.015

Review 6.  Lymphatics in intestinal transport of nutrients and gastrointestinal hormones.

Authors:  Alison Kohan; Stephanie Yoder; Patrick Tso
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

7.  Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.

Authors:  Sifei Han; Tim Quach; Luojuan Hu; Anisa Wahab; William N Charman; Valentino J Stella; Natalie L Trevaskis; Jamie S Simpson; Christopher J H Porter
Journal:  J Control Release       Date:  2014-01-05       Impact factor: 9.776

8.  Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs.

Authors:  Arik Dahan; Amnon Hoffman
Journal:  Eur J Pharm Sci       Date:  2005-03       Impact factor: 4.384

Review 9.  Role of the lymphatic system in the pathogenesis of Crohn's disease.

Authors:  Pierre-Yves von der Weid; Sonia Rehal; José Gp Ferraz
Journal:  Curr Opin Gastroenterol       Date:  2011-07       Impact factor: 3.287

10.  Increased proliferative response of lymphocytes from intestinal lymph during long chain fatty acid absorption.

Authors:  S Miura; H Imaeda; H Shiozaki; N Ohkubo; H Tashiro; H Serizawa; M Tsuchiya; P Tso
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

View more
  8 in total

Review 1.  Targeting Lymphatics for Nanoparticle Drug Delivery.

Authors:  Jacob McCright; Ritika Naiknavare; Jenny Yarmovsky; Katharina Maisel
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

2.  Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport.

Authors:  Tim Quach; Luojuan Hu; Sifei Han; Shea F Lim; Danielle Senyschyn; Preeti Yadav; Natalie L Trevaksis; Jamie S Simpson; Christopher J H Porter
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

3.  Intestinal Lymph Collection via Cannulation of the Mesenteric Lymphatic Duct in Mice.

Authors:  Babak Banan; Yan Wei; Ornella Simo; Patrick Tso; Naji N Abumrad; Charles Robb Flynn; Sinju Sundaresan; Vance L Albaugh
Journal:  J Surg Res       Date:  2020-11-28       Impact factor: 2.192

4.  A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy.

Authors:  Brian D Ross; Youngsoon Jang; Amanda Welton; Christopher A Bonham; Dilrukshika S W Palagama; Kevin Heist; Jagadish Boppisetti; Kasun P Imaduwage; Tanner Robison; Leah R King; Edward Z Zhang; Cyrus Amirfazli; Kathryn E Luker; Winston Y Lee; Gary D Luker; Thomas L Chenevert; Marcian E Van Dort
Journal:  Nat Commun       Date:  2022-08-17       Impact factor: 17.694

5.  Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative.

Authors:  Samaa Alrushaid; Casey L Sayre; Jaime A Yáñez; M Laird Forrest; Sanjeewa N Senadheera; Frank J Burczynski; Raimar Löbenberg; Neal M Davies
Journal:  Pharmaceutics       Date:  2017-09-13       Impact factor: 6.321

6.  Gut Ischemia Reperfusion Injury Induces Lung Inflammation via Mesenteric Lymph-Mediated Neutrophil Activation.

Authors:  Yonggang Ma; Taylor Zabell; Alexandra Creasy; Xiaoyuan Yang; Victor Chatterjee; Nuria Villalba; Erik B Kistler; Mack H Wu; Sarah Y Yuan
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561

Review 7.  Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?

Authors:  Michael Mah; Mark Febbraio; Sarah Turpin-Nolan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-27       Impact factor: 5.555

Review 8.  The Gut-Lung Axis in Systemic Inflammation. Role of Mesenteric Lymph as a Conduit.

Authors:  Yonggang Ma; Xiaoyuan Yang; Victor Chatterjee; Mack H Wu; Sarah Y Yuan
Journal:  Am J Respir Cell Mol Biol       Date:  2021-01       Impact factor: 6.914

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.